Hanmi Pharmaceutical
128940 · KOSPI · South Korea
Public Market Listing
128940KOSPI
Live quotes, historical charts, and market capitalization for Hanmi Pharmaceutical are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(5 total)
5Total Assets
0Approved
1Phase 3 / Filed
4Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1 receptorPeptide | ObesityType 2 Diabetes | |
| Phase 2 | GLP-1/GIP/glucagon receptor (triple)Peptide | ObesityMASH / NASH | |
| Phase 2 | GLP-1/GIP/glucagon receptor (triple)Peptide | ObesityType 2 Diabetes | |
| Phase 1/2 | FLT3 (wild-type and mutant, including ITD/TKD), SYK, JAK1/2, mutant KIT, RSK2Small molecule | Acute Myeloid Leukemia | |
Entecavir (Cavir)No recent activity | Phase 1 | HBV polymerase (reverse transcriptase)Small molecule | Chronic Hepatitis B |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
January 2027 (1)
October 2027 (1)
November 2027 (1)
Est. primary completion 2027-11 · NCT07379333 · CT.gov ↗